Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RN7SL679P refers to a human pseudogene derived from the 7SL RNA, a non-coding RNA that in its functional (not pseudogene) form is a core component of the signal recognition particle (SRP)[1][3][5]. RN7SL679P itself does not encode a functional product; it is classified as a pseudogene because it contains sequence similarity to the functional 7SL RNA gene but lacks evidence of expression or biological activity. Most human 7SL-derived loci (including RN7SL679P) are thought to have arisen by retrotransposition and typically do not produce stable transcripts or have known functions[3][4]. While functional 7SL RNA is crucial for co-translational targeting of proteins to the endoplasmic reticulum, pseudogenes like RN7SL679P are not considered therapeutic targets and have no identified role as receptors, enzymes, or other druggable entities. Some pseudogenes may serve as sources of regulatory non-coding RNAs in specific contexts[4], but RN7SL679P specifically has no documented regulatory, disease, or drug-interaction roles. Additional context: - The large family of 7SL pseudogenes do not contribute to SRP function and are present in many genomic loci as non-functional copies[3]. - In rare cases, pseudogenes can affect gene regulation (through small RNA production or as miRNA sponges[4]), but there is no specific evidence for this for RN7SL679P. - 7SL RNA itself (not pseudogenes) is sometimes upregulated in cancer and present in extracellular vesicles[5], but this relates to the functional gene and not RN7SL679P. In summary, RN7SL679P is a non-functional pseudogene with no evidence of protein product or therapeutic relevance; its inclusion as a target or receptor is incorrect[3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, 7SL, cytoplasmic 679, pseudogene (RN7SL679P).